Cynthia is a seasoned investment professional with nineteen years’ experience in venture capital. Prior to co-founding AllosteRx, Cynthia was a General Partner with TVM Capital, a global fund with main offices in Munich and Montreal. She was recruited to TVM from VG Partners where she was partner and co-head of the life sciences fund. Cynthia has taken active roles on boards of companies including Acer Therapeutics (NASDAQ: ACER), Cytochroma (acquired by OPKO Health), VisualSonics (acquired by SonoSite, now FujiFilm SonoSite), and Trillium Therapeutics (NASDAQ: TRIL, acquired by Pfizer). Cynthia is currently board director of CCRM Enterprises portfolio companies Morphocell Technologies, developing cell therapies for liver disease, and Apiary Therapeutics, a start-up developing cell-based protein factory technologies. Along with her role as Chair of the Fibrocor Board, Cynthia is also Board Director at Profound Medical (NASDAQ:PROF, TSX:PRN). Dr. Lavoie received a PhD from McGill University and MBA from the Rotman School of Management at the University of Toronto.

Keno has over 25 years of Biotech experience spanning operations (CEO of Brandaris Therapeutics), investing (private and public equities at M Ventures and Omega Funds), investment banking (Piper Sandler), management consulting (IQVIA), and medical research (MRC). Prior to joining BGV, Keno was as Managing Director and Vice President at M Ventures responsible for Biotech investments (Biopharma and Life Sciences).
Keno is a Fellow of the Royal Society of Medicine, holds a PhD in Genetics from University College in London and an MBA from INSEAD. He is the inventor of a patent in the field of neurosciences. His research in lipid metabolism has been published in the top scientific journal Nature.

His track record spans private and public companies, startups and large corporations, and different business models, healthcare verticals and emerging sectors.  As a leader and strategist, he has held responsibility for people, P&Ls, financing, licensing, M&A, and go-public leadership. He currently serves as Interim CEO at TIAP, a not-for-profit that identifies and accelerates medical innovations into high-potential Canadian companies, leading investment strategy, company mentorship, and portfolio management.   Prior to TIAP, Prakash was Chief Operating Officer and Head of Corporate Development at a mental health and psychedelic medicine company, where he led the development of a clinic network, took the company public, managed U.S. operations, and oversaw acquisitions and the eventual sale of the business.  Previously, as co-founder of a health technology company focused on individualized treatment strategies in a newly regulated market, he helped build the team, launch the product, and guide the company through to acquisition. Prakash is also an experienced capital markets professional, having served in senior biotech equity research and investment banking roles at CIBC World Markets, National Bank Financial, and Canaccord Capital.  The foundation of his career was built over many years in commercial operations and new product development in the pharmaceutical industry. Prakash serves on the boards of BioSyent (RX-TSXV), Appili Therapeutics (APLI-TSX), HDAX Therapeutics, Vasomune, Klondike, Bright Angel Therapeutics, and has previously served as Director at FendX Technologies and Isotechnika Pharma (now Aurinia Pharmaceuticals). He holds an MBA from McGill University, degrees in Pharmacy and Zoology from the University of British Columbia, and is a Chartered Director.

During his >40 year career in biotech, he held positions at Genentech Inc. (postdoctoral scientist), Syngenta and DSM (Research and Project Management), Crucell (Director of Business Development), and Invitrogen Corporation (Managing Director of Corp Dev Europe).
From 2005 until his retirement in January 2023, Andre was CBO and member of the Galapagos Executive Committee, responsible for M&A, BD and IP. Andre negotiated 15 large pharma drug discovery partnerships, and was the lead negotiator of the landmark partnership with Gilead in 2019. As part of the Galapagos growth strategy, Andre negotiated 7 acquisitions and led the divestment of 4 parts of the CRO business.
He currently serves as a member of the supervisory boards of Artax Inc (Boston, MA), Mimetas BV and Sapreme BV (both located in Holland).

Prior to joining Lakefront, Jay was a Principal at Abingworth, a leading transatlantic life sciences venture firm, where he played a key role in investments in companies including R1 Therapeutics, Timberlyne Therapeutics, and Escient Pharma. Before Abingworth, he served as a Director at AbbVie Ventures, focusing on equity investments in early-stage biotech companies in autoimmune, oncology and neuroscience.   Jay began his career as a business consultant and holds both an MBA and a PhD in Organic Chemistry from the University of Chicago.